[go: up one dir, main page]

NO960651D0 - Farmasöytiske preparater av nervevekstfaktor - Google Patents

Farmasöytiske preparater av nervevekstfaktor

Info

Publication number
NO960651D0
NO960651D0 NO960651A NO960651A NO960651D0 NO 960651 D0 NO960651 D0 NO 960651D0 NO 960651 A NO960651 A NO 960651A NO 960651 A NO960651 A NO 960651A NO 960651 D0 NO960651 D0 NO 960651D0
Authority
NO
Norway
Prior art keywords
growth factor
nerve growth
pharmaceutical preparations
lyophilization
admixed
Prior art date
Application number
NO960651A
Other languages
English (en)
Other versions
NO960651L (no
NO317627B1 (no
Inventor
Victoria M Knepp
Deborah M Lidgate
Richard Maskiewicz
Leo Gu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO960651L publication Critical patent/NO960651L/no
Publication of NO960651D0 publication Critical patent/NO960651D0/no
Publication of NO317627B1 publication Critical patent/NO317627B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19960651A 1993-08-20 1996-02-19 Vandig, farmasoytiske preparater av nervevekstfaktor NO317627B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/109,798 US6277828B1 (en) 1993-08-20 1993-08-20 Pharmaceutical formulations of nerve growth factor
PCT/US1994/009245 WO1995005845A1 (en) 1993-08-20 1994-08-16 Pharmaceutical formulations of nerve growth factor

Publications (3)

Publication Number Publication Date
NO960651L NO960651L (no) 1996-02-19
NO960651D0 true NO960651D0 (no) 1996-02-19
NO317627B1 NO317627B1 (no) 2004-11-29

Family

ID=22329623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960651A NO317627B1 (no) 1993-08-20 1996-02-19 Vandig, farmasoytiske preparater av nervevekstfaktor

Country Status (31)

Country Link
US (2) US6277828B1 (no)
EP (1) EP0721343B1 (no)
JP (2) JP4592830B2 (no)
KR (1) KR100341193B1 (no)
CN (1) CN1163265C (no)
AT (1) ATE226085T1 (no)
AU (1) AU677699B2 (no)
BG (1) BG62951B1 (no)
BR (1) BR9407278A (no)
CA (1) CA2169834C (no)
CZ (1) CZ292422B6 (no)
DE (1) DE69431562T2 (no)
DK (1) DK0721343T3 (no)
ES (1) ES2181723T3 (no)
FI (1) FI113241B (no)
HU (1) HU228152B1 (no)
IL (3) IL124941A (no)
LT (1) LT4051B (no)
LV (1) LV11279B (no)
NO (1) NO317627B1 (no)
NZ (1) NZ271873A (no)
PL (1) PL176387B1 (no)
PT (1) PT721343E (no)
RO (1) RO114742B1 (no)
RU (1) RU2126265C1 (no)
SI (1) SI9420048B (no)
SK (1) SK284064B6 (no)
TW (1) TW427905B (no)
UA (1) UA43348C2 (no)
WO (1) WO1995005845A1 (no)
ZA (1) ZA946333B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
EP0831883A1 (en) * 1995-05-12 1998-04-01 The Rockefeller University Treatment of alzheimer disease by modulation of synapsins
US6964947B1 (en) * 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
US6090781A (en) * 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
EP0862452B1 (en) * 1995-11-07 2003-12-10 Genentech, Inc. Stabilizing formulation for ngf
EP1015826A2 (en) * 1996-05-29 2000-07-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
CN1059597C (zh) * 1996-08-08 2000-12-20 陈素兰 神经损伤修复制剂
DK0994721T3 (da) * 1997-05-01 2007-04-02 Protechtion Unltd Inc Nervevækstfaktor som vaccineadjuvans
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
WO2003055512A1 (en) 2001-12-21 2003-07-10 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE454900T1 (de) * 2003-05-23 2010-01-15 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
KR20120104619A (ko) * 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
CN1917861B (zh) * 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
AU2007285215A1 (en) * 2006-08-14 2008-02-21 Eisai R & D Management Co., Ltd. Stable lyophilized preparation
JP4111995B1 (ja) * 2006-11-08 2008-07-02 株式会社メディカル・アプライアンス 神経栄養因子産生促進装置
EP1958618A1 (de) * 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
EP2349338A2 (fr) * 2008-09-26 2011-08-03 Adocia Complexe constitue d'un polysaccharide et d'une hpb
CN102232932B (zh) * 2010-04-27 2013-06-05 重庆莱美药业股份有限公司 果胶-阿霉素轭合物的冻干制剂及制备方法
PT2694094T (pt) 2011-04-07 2017-11-06 Neovacs Método para tratar afeções relacionadas com ifn alfa
WO2013117729A1 (en) * 2012-02-08 2013-08-15 Institut National De La Recherche Agronomique Use of beta-nerve growth factor for inducing ovulation in mammals
CN108348579B (zh) * 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 神经生长因子组合物及注射粉剂
EP3287140B1 (en) * 2015-04-21 2021-06-02 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
EP3287141B1 (en) * 2015-04-21 2021-08-18 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and injection powder
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
US20200299371A1 (en) 2016-03-25 2020-09-24 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
JP7109427B2 (ja) * 2016-06-01 2022-07-29 セルヴィエ アイピー ユーケー リミテッド ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
CN109260147B (zh) * 2018-10-15 2019-09-13 珠海亿胜生物制药有限公司 一种用于治疗或预防神经损伤的重组人碱性成纤维细胞生长因子注射剂
US11767504B2 (en) 2020-08-14 2023-09-26 Albcura Corporation Albumin compositions and methods of producing and using same
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4497431A1 (en) * 2023-07-27 2025-01-29 Dompé farmaceutici S.p.A. Pharmaceutical formulation comprising nerve growth factor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
NZ235556A (en) 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH0418031A (ja) * 1989-02-16 1992-01-22 Hiroshi Saito 損傷治癒促進剤
US5169834A (en) * 1990-11-30 1992-12-08 American Cyanamid Company Compositions and method for reducing vial breakage during lyophilization
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
JP3283288B2 (ja) * 1991-03-08 2002-05-20 電気化学工業株式会社 生理活性ペプチド製剤
JP2818834B2 (ja) * 1991-08-12 1998-10-30 大塚製薬株式会社 ＩＬ−１α安定化医薬製剤

Also Published As

Publication number Publication date
AU677699B2 (en) 1997-05-01
CN1163265C (zh) 2004-08-25
EP0721343A1 (en) 1996-07-17
PL313084A1 (en) 1996-05-27
IL124941A0 (en) 1999-01-26
JP2007314572A (ja) 2007-12-06
IL110725A (en) 2004-09-27
LV11279A (lv) 1996-06-20
SK284064B6 (sk) 2004-09-08
HK1012990A1 (en) 1999-08-13
FI960750L (fi) 1996-02-20
DE69431562D1 (de) 2002-11-21
NO960651L (no) 1996-02-19
BG100371A (bg) 1996-12-31
US7074763B2 (en) 2006-07-11
CZ292422B6 (cs) 2003-09-17
ATE226085T1 (de) 2002-11-15
US20010007662A1 (en) 2001-07-12
SI9420048A (en) 1996-10-31
DE69431562T2 (de) 2003-06-18
WO1995005845A1 (en) 1995-03-02
BR9407278A (pt) 1996-10-01
KR100341193B1 (ko) 2002-06-21
HU228152B1 (en) 2012-12-28
FI960750A0 (fi) 1996-02-19
IL110725A0 (en) 1994-11-11
CZ42496A3 (en) 1996-05-15
JP4592830B2 (ja) 2010-12-08
SK18396A3 (en) 1996-10-02
HUT74728A (en) 1997-02-28
JPH10508000A (ja) 1998-08-04
RO114742B1 (ro) 1999-07-30
LV11279B (en) 1996-10-20
ZA946333B (en) 1996-02-19
UA43348C2 (uk) 2001-12-17
CN1133012A (zh) 1996-10-09
FI113241B (fi) 2004-03-31
SI9420048B (sl) 2003-12-31
EP0721343B1 (en) 2002-10-16
LT96011A (en) 1996-07-25
CA2169834A1 (en) 1995-03-02
NO317627B1 (no) 2004-11-29
ES2181723T3 (es) 2003-03-01
TW427905B (en) 2001-04-01
CA2169834C (en) 2008-11-04
IL124941A (en) 2006-12-10
AU7566894A (en) 1995-03-21
US6277828B1 (en) 2001-08-21
BG62951B1 (bg) 2000-12-29
DK0721343T3 (da) 2003-02-17
NZ271873A (en) 1996-10-28
RU2126265C1 (ru) 1999-02-20
HU9600371D0 (en) 1996-04-29
LT4051B (en) 1996-10-25
PT721343E (pt) 2003-01-31
PL176387B1 (pl) 1999-05-31

Similar Documents

Publication Publication Date Title
NO960651L (no) Farmasöytiske preparater av nervevekstfaktor
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
DK66692D0 (da) En mammal cytokin, il-11
FI881736L (fi) Olutmäskiuutteen käyttö kosmeettisten valmisteiden valmistukseen, kosmeettinen valmiste ja olutmäskiuute
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
UA26855C2 (uk) Фармацевтичhа композиція, яка регулює гематопоез
FI881061A7 (fi) Hitaasti vapauttavia valmisteita ruoansulatuskanavan ulkopuolisesti annettaviksi ja niiden käyttö.
BR9611571B1 (pt) composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
AU626033B2 (en) Methods for the treatment and prophylaxis of pneumocystis carinii pneumonia and other diseases and compounds and formulations for use in said methods
AU2231688A (en) Stabilisation of therapeutically active proteins in a pharmaceutical composition
DK229387A (da) Retinoesyreestere, deres fremstilling og farmaceutiske og kosmetiske praeparater deraf
FI880636A7 (fi) Menetelmä vaipallisten virusten inaktivoimiseksi solun avulla in vitro valmistetuissa proteiinivalmisteissa.
AU5608798A (en) Formulations of recombinant papillomavirus vaccines
AU8769791A (en) Pharmaceutically active proteins comprising an active protein and an integrinaffinity sequence
NO911788D0 (no) Galeniske vandige preparater av erytropoietin.
DE3777411D1 (de) Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln.
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання
DK326985A (da) Farmaceutiske og kosmetiske praeparater indeholdende et anthracenderivat som aktiv bestanddel
IT8921516A0 (it) Procedimento di microincapsulazione di microorganismi vivi e composizioni farmaceutiche stabili.
FI945635L (fi) Uudet entsyymivalmisteet ja niiden valmistusmenetelmät
NO905375L (no) Fremg. og preparater for behandling av pattedyr-infeksjoner under anv. av medikamenter som omfatter hymenoptera venom, protein- eller polypepti-komponenter derav, eller analoger av slike protein- eller polypeptid-komponenter.
UA30787A (uk) Спосіб лікування хронічного персистуючого гепатиту

Legal Events

Date Code Title Description
MK1K Patent expired